Additionally, EBV-positive DLBCL is reportedly characterized by frequent mutations in TET2 and DNMT3A and the paucity of alterations in CD79B, MYD88, CDKN2A, and FAS. This evidence concerns the gene DNMT3A and diffuse large B-cell lymphoma.